Study of Cabozantinib in Participants With Neuroendocrine Tumors Who Have Already Received Prior Treatment

Recruiting now

Conditions studied: Neuroendocrine Tumors

In brief

This study will assess how well cabozantinib works and how safe it is in adults with a type of cancer called neuroendocrine tumors (NETs). These tumors can appear in all parts of the body. All participants in this study have already received at least one treatment that affects the whole body to help manage their cancer, but their disease has continued to grow. The study will take place in regular hospitals and clinics in Germany and Austria. It will follow about 150 participants who are taking cabozantinib as part of their usual care. Doctors will collect information from routine medical visits, tests, and scans to see how the cancer responds to treatment and how long participants stay on cabozantinib. They will also look at side effects and how the treatment affects participants' quality of life. This is an observational study, which means that no extra tests or procedures will be done beyond what is normally used to care for participants with this condition.

Key facts

Study ID

NCT07314164

Run by

Ipsen

People needed

150

Starts

2025-12-17

Expected to finish

2028-12-31

Last updated by the study team

2026-07-01

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Participants can join the study if they meet all of the following conditions:
• Are 18 years or older and able to give informed consent.
• Have a physician-initiated decision to start treatment with cabozantinib for neuroendocrine tumors (NETs), made before joining the study.
• Have unresectable or metastatic, well-differentiated pancreatic (pNET) or extra-pancreatic neuroendocrine tumors (epNET).
• Have already received at least one prior systemic therapy, other than somatostatin analogues.
• Have signed a written informed consent form.

You may not qualify if…

• Participants cannot join the study if:
• They are currently participating in an interventional clinical trial, or have done so within the last 3 months before joining this study.
• They have a contraindication to cabozantinib treatment, based on the product's official prescribing information.

Where it is running

• Medizinische Universitaet Graz — Graz, Austria (enrolling)
• DRK Kliniken Berlin — Berlin, Germany (enrolling)
• Evangelische Lungenklinik Berlin — Berlin, Germany (enrolling)
• Krankenhaus St. Joseph-Stift Bremen GmbH — Bremen, Germany (enrolling)
• pioh Studien und Mangement GbR — Cologne, Germany (enrolling)
• Gemeinschaftspraxis Haematologie - Onkologie — Dresden, Germany (enrolling)
• Technische Univiersitaet (TU) Dresden — Dresden, Germany (enrolling)
• Universitaetsklinikum Essen — Essen, Germany (enrolling)
• Universitaetsmedizin Goettingen — Goettigen, Germany (enrolling)
• Universitaetsklinikum Hamburg-Eppendorf — Hamburg, Germany (enrolling)
• RKH Kliniken Ludwigsburg-Bietigheim gGmbH — Ludwigsburg, Germany (enrolling)
• Philipps-Universitaet Marburg — Marburg, Germany (enrolling)
• MVZ Muelheim an der Ruhr GmbH — Mülheim, Germany (enrolling)
• Universitätsklinikum Tuebingen — Tübingen, Germany (enrolling)
• Medizinische Studiengesellschaft Nord-West — Westerstede, Germany (enrolling)
• Universitaetsklinikum Wuerzburg — Würzburg, Germany (enrolling)
• Medizinische Universität Wien — Vienna, Austria (enrolling)
• MVZ am Klinikum Aschaffenburg — Aschaffenburg, Germany (enrolling)
• Charité - Universitaetsmedizin Berlin — Berlin, Germany (enrolling)
• Kepler Universitaetsklinikum GmbH Linz — Linz, Austria
• Uniklinikum Frankfurt — Frankfurt am Main, Germany
• Universitaetsklinikum Freiburg — Freiburg im Breisgau, Germany
• Universitaetsklinikum Giessen-Marburg — Giesen, Germany
• MVZ Onkologie Klinikum Osnabrueck GmbH — Osnabrück, Germany
• Asklepios Kliniken Hamburg — Hamburg, Germany

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.